Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patheon, a global provider of drug development and manufacturing services, has received two projects worth over $18m, from Boehringer Ingelheim to develop fixed-dose combination drugs in the treatment of type II diabetics.
Subscribe to our email newsletter
The projects span over a period of three years.
Patheon president and chief scientific officer Mark Kontny said Boehringer has recognized their capabilities in formulating, scaling and launching complex formulations.
"It is this kind of support and recognition that has enabled us to develop our market leading position in pharmaceutical development services," Kontny added.